Pharsight

Consensi is owned by Purple Biotech.

Consensi contains Amlodipine Besylate; Celecoxib.

Consensi has a total of 5 drug patents out of which 0 drug patents have expired.

Consensi was authorised for market use on 31 May, 2018.

Consensi is available in tablet;oral dosage forms.

Consensi can be used as treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate.

The generics of Consensi are possible to be released after 14 June, 2038.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662315	PURPLE BIOTECH	Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs	May, 2029 (5 years from now)
US9408837	PURPLE BIOTECH	Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs	Feb, 2030 (6 years from now)
US10925835	PURPLE BIOTECH	Celecoxib and amlodipine formulation and method of making the same	Jun, 2038 (15 years from now)
US10945960	PURPLE BIOTECH	Celecoxib and amlodipine formulation and method of making the same	Jun, 2038 (15 years from now)
US10350171	PURPLE BIOTECH	Celecoxib and amlodipine formulation and method of making the same	Jun, 2038 (15 years from now)